Tag: GlobeNewswire

University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection

MOUNTAIN VIEW, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, announced today that the first patient has enrolled in PRISM-TAMP, “PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP,” an investigator-initiated trial (IIT) sponsored by the University of Vermont (UVM). One week after the IIT began, a second patient is also progressing toward TAMP treatment.

PRISM-TAMP is evaluating the approved chemotherapy gemcitabine delivered through RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP) platform, enabled by RenovoCath, as neoadjuvant treatment before surgery in patients with borderline Pancreatic Ductal Adenocarcinoma (PDAC). PRISM-TAMP is the first RenovoRx supported IIT to advance to patient enrollment. UVM plans to enroll approximately 10 patients and is registered on ClinicalTrials.gov (NCT07477418). The primary focus of PRISM-TAMP is to assess PDAC tumor regression, the impact on intraoperative surgical margins following neoadjuvant (pre-surgical) treatment, and overall safety and tolerability.

In borderline resectable pancreatic cancer, the tumor involves nearby blood vessels to a degree that can make complete surgical removal difficult. Patients typically receive chemotherapy, with or without radiation, before surgery, and typically receive such treatment systemically, rather than administered locally near the tumor site as TAMP is designed to do.

“For patients with borderline resectable pancreatic cancer, treatment before surgery can influence both whether surgery is possible and how completely the tumor can be removed,” said Conor O’Neill, MD, Assistant Professor at the UVM Larner College of Medicine and surgical oncologist at the UVM Medical Center, and principal investigator of PRISM-TAMP. “PRISM-TAMP will assess whether delivering chemotherapy directly near the tumor through TAMP before surgery can improve local therapeutic response and surgical outcomes. We are pleased to have enrolled our first patient in this important study.”

“As TAMP becomes more well known in the marketplace, physicians have asked how TAMP could be used in borderline resectable pancreatic cancer and other settings beyond locally advanced pancreatic cancer, which is the focus of our ongoing Phase III clinical trial,” said Leesa Gentry, Chief Clinical Officer of RenovoRx. “Enrolling the first PRISM-TAMP patient marks an important step for our IIT program as it moves from concept to clinical execution. These capital-efficient trials enable independent investigators to generate safety and tolerability data of new applications for TAMP, while we remain focused on completing the Phase III TIGeR-PaC trial and reporting topline data in the second half of 2027.”

UVM is evaluating RenovoRx’s novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath (known as IAG) within the PRISM-TAMP study.

About RenovoCath

Based on its FDA clearance, RenovoCath^® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-H-Universal-IFU.pdf.

About RenovoRx, Inc.

RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a standalone device. For its first full year of commercial efforts in 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, followed by record quarterly revenue of $909,000 in the second quarter of 2026. RenovoRx is actively working to expand the number of medical institutions initiating new RenovoCath orders, including esteemed, high-volume National Cancer Institute-designated centers.

RenovoRx is also evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, which is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx achieved full enrollment in the TIGeR-PaC trial in August 2026, with completion of the trial expected in the first half of 2027 and topline data readout expected in the second half of 2027.

The IAG combination product candidate, enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation (ODD) for pancreatic cancer and bile duct cancer, and oxaliplatin has received ODD for pancreatic cancer, each of which provides seven years of market exclusivity upon new drug application approval by the FDA.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of the Company’s management and third parties made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies (including IITs and including our expectations for trial completion and interim or final data read out), (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and TAMP technology for use in treating pancreatic and other solid tumor cancers, and our expected financial results from such efforts, including our estimates for 2026 annual revenue. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, commercial and other business plans, intellectual property development, clinical trials, our therapy platform, financing plans, objectives, and expected operating results, all of which are based on current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “aim,” “goal,” “estimates,” “intends,” and “potential,” or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about the future, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial efforts for our TAMP technology (enabled by RenovoCath) may not lead to the achievement of our revenue forecasts or to viable, revenue generating operations in general; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress, completion and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, IITs, and our research programs (notably with respect to our TIGeR-PaC trial); (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our ability to obtain additional capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; (xvii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xviii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission, which can be accessed at https://ir.renovorx.com/sec-filings.

As a result of the foregoing, readers are cautioned to not place undue reliance on forward-looking statements, which do not represent promises or guarantees by RenovoRx. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Investor Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
renovorx@kcsa.com

Media Contact:
STiR Communications
Hannah Williams
T: 803-521-1214
hannah@stir-communications.com

TOMI Environmental Solutions is positioned to meet increased preparedness requests following the suspected pneumonic plague case reported in Russia

FREDERICK, Md., Oct. 07, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.^® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today confirmed that it is prepared to support any increase in request for preparedness planning, equipment and decontamination services, and to provide front-line support for local or regional outbreaks anywhere in the world.

This is followed by the recent public reports regarding the death of a laboratory worker at an anti-plague research institute in Russia’s Irkutsk region, with approximately 200 individuals placed under medical observation. Russian health authorities have described the case as pneumonia of unknown origin, and the cause has not been officially confirmed. Independent public health experts have said that a wider epidemic appears unlikely, and the pneumonic plague is treatable with antibiotics when diagnosed promptly. TOMI is closely monitoring the situation.

Events of this kind prompt hospitals, laboratories, emergency services and government agencies to review their own readiness. TOMI is prepared to support those efforts with SteraMist systems that are ready to deploy, on-site decontamination through its service department, and the reach of its global partner network.

“Preparedness is built before it is needed,” stated Dr. Halden Shane, CEO of TOMI Environmental Solutions. “Our technology, service team and partners are in place, and we are ready to support health systems, laboratories, and responders wherever they ask for it. We will continue to follow the guidance of public health authorities and respond to requests as they come.”

Organizations seeking preparedness support or service deployment can contact TOMI at info@tomimist.com or SteraMist.com.

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company providing environmental disinfection and bio-decontamination solutions through manufacturing, sales, and licensing of its Binary Ionization Technology® (BIT®) platform. Developed under a defense grant with DARPA, BIT® utilizes low-percentage hydrogen peroxide to produce ionized hydrogen peroxide (iHP®) fog. SteraMist® products serve hospitals, laboratories, government and military installations, cruise ships, office buildings, schools, restaurants, food processing facilities, and residences, delivering protection against a broad range of bacteria, viruses, mold, mycotoxins, and biological and chemical warfare agents. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.

Forward-Looking Statements 
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services for emergency preparedness and outbreak response. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT: 
John Nesbett/Zach Nevas
IMS Investor Relations 
tomi@imsinvestorrelations.com

Preclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, differentiation-based mechanism with the clinical benchmark set by RASONQUE (daraxonrasib)

MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today highlighted new preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC) and compared that profile with a clinical standard recently established by Revolution Medicines, Inc.

On August 26, 2026, the U.S. Food and Drug Administration approved daraxonrasib (RASONQUE), Revolution Medicines’ oral RAS(ON) multi-selective inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy. Approval was based on the Phase 3 RASolute 302 trial. In the RAS G12 population, daraxonrasib delivered median overall survival of 13.2 months versus 6.6 months with chemotherapy (hazard ratio 0.40), median progression-free survival of 7.3 months versus 3.5 months (hazard ratio 0.45), and a confirmed objective response rate of 33.2% versus 11.8%. Results in the intent-to-treat population were consistent: median overall survival 13.2 versus 6.7 months (hazard ratio 0.40) and median progression-free survival 7.2 versus 3.6 months (hazard ratio 0.49).

Those data validate RAS as a druggable driver in a disease in which RAS mutations are present in roughly 90% of cases. They also leave a defined residual problem: epithelial-mesenchymal transition (EMT), cancer stem cells, fibrosis, and metastatic dissemination are not the primary targets of RAS pathway blockade.

PRP is a proprietary intravenous fixed-ratio combination of the pancreatic proenzymes, trypsinogen and chymotrypsinogen (1:6). It does not inhibit RAS. In orthotopic and patient-derived xenograft models of advanced PDAC, three-times-weekly intravenous PRP produced:

• >90%, mean, tumor growth inhibition, versus vehicle (p < 0.001), building on previously reported inhibition above 85%.
• A marked reduction in metastatic burden in the liver and peritoneum.
• Remodeling of the tumor microenvironment, including lower cancer-associated fibroblast activity, less fibrosis, and suppression of EMT markers.
• Greater sensitivity of chemo-resistant PDAC cells to gemcitabine plus nab-paclitaxel, supporting the potential for lower chemotherapy doses with improved activity.
• A median overall survival extension of more than 2.5-fold versus controls.

Limited prior compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival in advanced solid-tumor patients, with a favorable safety profile and no severe treatment-related adverse events reported in that experience. PRP holds FDA Orphan Drug Designation Status for the treatment of pancreatic cancer and is not restricted to the RAS genotype.

“Daraxonrasib is a genuine advancement for patients with metastatic pancreatic cancer, and the RASolute 302 survival benefit is the clinical benchmark the field now has to beat or complement,” said James Nathanielsz, Propanc’s Chief Executive Officer. “PRP is aimed at a different node. The preclinical package — deep tumor control, fewer metastases, a less fibrotic microenvironment, and chemo re-sensitization — is the biology RAS inhibition does not directly address. We see PRP as a potential combination or sequential partner, not a substitute, and we are moving it into patients.”

The Company plans to start a multicenter, open-label Phase 1b first-in-human study of PRP in the first quarter of 2027. The study is expected to enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at sites across Australia.

Comparative Summary

Attribute	PRP	Daraxonrasib / RASONQUE
Modality	IV proenzyme combination (trypsinogen + chymotrypsinogen, 1:6)	Oral RAS(ON) multi-selective inhibitor
Primary biology	Differentiation, EMT reversal, cancer stem cells, fibrosis, metastasis	Oncogenic RAS(ON) signaling
Stage	Preclinical PDAC plus clinical efficacy evaluated in advanced cancer patients on compassionate grounds; Phase 1b planned Q1 2027	FDA-approved August 26, 2026; Phase 3 RASolute 302
PDAC activity reported	>90% mean tumor-growth inhibition; >2.5-fold median survival in animal models; reduced liver and peritoneal metastases	mOS 13.2 vs 6.6–6.7 months; mPFS 7.2–7.3 vs 3.5–3.6 months; ORR ~32% vs ~12%
Genotype	Not RAS-mutation restricted; FDA Orphan Drug Designation Status in pancreatic cancer	FDA Approved in metastatic pancreatic adenocarcinoma after prior therapy, activity shown across RAS G12 and overall populations

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780

info@propanc.com

Investor Contact:

irteam@propanc.com

Licence of up to 20 years, payable in shares, as Malaysia commits RM1 billion to digitalizing public healthcare

KUALA LUMPUR, Malaysia, Oct. 07, 2026 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“Company” or “BGLC”) today announced plans to build AI applications for Malaysian healthcare, following the signing of a definitive agreement with Ruanyun Edai Technology Inc. (Nasdaq: RYET) on October 5, 2026 for an exclusive Malaysian healthcare licence to RYET’s CogniAI artificial intelligence platform. BGLC’s first target is Malaysia’s public healthcare digitalization programme, which covers 150 hospitals and more than 2,000 health clinics. Closing and the contemplated share issuances remain pending.

“With CogniAI we would not be starting from a blank page,” said Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp. “The platform exists and is in commercial use, and our job is to build the applications around it. Malaysia is putting real money into taking public healthcare records digital, and that is where we intend to go first.”

The opportunity

In August 2026, the Malaysian government raised its allocation for public healthcare digitalization to RM1 billion, covering electronic medical records and connectivity at 150 hospitals and more than 2,000 health clinics. The Ministry of Health has said public hospitals and health facilities nationwide are to be equipped with electronic medical records by 2029. Its facilities recorded 68.2 million patient arrivals in 2023, according to ministry data tabled in Parliament in 2025.

BGLC intends to offer CogniAI-based applications that complement those systems by bringing existing paper and scanned records into digital form. BGLC has not been awarded any government contract, and any public-sector work would depend on government procurement.

More broadly, a November 2024 report by Grand View Research projects the global intelligent document processing market to reach approximately US$12.35 billion by 2030, growing at about 33.1% a year from 2025. Notably, the agreement also gives BGLC a right to add other Malaysian industries by written notice, which would allow it to pursue digitalization work beyond healthcare.

A platform already in commercial use

CogniAI is RYET’s AI platform for document intelligence. It recognizes, classifies and extracts information from documents and records. In June 2026, RYET reported approximately US$1.73 million of contracted commercial activity for the platform, on an unaudited basis. In September 2026, it announced a deployment to digitize highway engineering archives in Ningxia, China.

“BioNexus knows the Malaysian market and its healthcare providers, and that local knowledge is what turns a platform into working applications,” said Maggie Fu, Chief Executive Officer of Ruanyun Edai Technology Inc. “We built CogniAI to read and organize records at scale, and we look forward to supporting BioNexus as it takes the platform into healthcare.”

At closing, BGLC would receive rights to host, adapt and integrate the platform, build and brand applications using it, and sublicense the technology to customers and implementation partners during the prescribed term. BGLC would lead local implementation and customer relationships, and it retains ownership of the applications it develops. Personal data must be hosted in Malaysia, with no RYET Group access from outside the country.

The licence adds a third element to the AI and technology strategy BGLC has been building. The first two are its investments, in Ascension Innovation Sdn. Bhd. in August 2024 and in Fidelion Diagnostics Pte. Ltd. in November 2025, when it also obtained exclusive ASEAN rights to the VitaGuard™ minimal residual disease platform, and its own GeneMatrix Systems software development.

Key terms of the RYET agreement

• Licence. Exclusive for healthcare in Malaysia for ten years from closing, with two five-year renewal options for BGLC. Exclusivity is subject to the agreement’s milestone, cure and termination provisions.
• Other industries. BGLC may add other Malaysian industries by written notice. Exclusivity in an added industry continues only if a customer contract is signed within twelve months. Additional RYET work would require a separate project agreement.
• Consideration. At closing, BGLC will issue 410,000 common shares for the stated US$3.5 million licence consideration, a contractual amount and not a statement of fair value. There is no cash payment or market-value guarantee.
• Share exchange. BGLC will issue another 150,000 common shares in exchange for 500,000 RYET ordinary shares, for 560,000 shares in total.
• Royalty to RYET. 10% of defined technology receipts actually collected, with no minimum royalty or annual platform fee. Testing and clinical fees and separately identifiable services are excluded.
• Closing. Subject to technology delivery and BGLC’s written acceptance, satisfactory due diligence, and required approvals. Either non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended.

Next steps

RYET is required to deliver the technology by December 4, 2026, which is 60 days after signing. BGLC will then carry out acceptance testing. In parallel, BGLC plans to begin discussions on offering CogniAI-based applications to government digitalization initiatives.

“We structured the agreement to keep cash in the business,” Mr. Tan said. “RYET is taking its licence consideration in our shares and a royalty only on what we collect, so it does well only if we do. The next step is practical. We take delivery, test the technology, and take it to the people running Malaysia’s healthcare digitalization.”

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a technology-focused company operating across biotechnology, precision diagnostics and specialty materials. Through its subsidiaries, investments and licensing arrangements, the Company is developing new healthcare and life-science businesses alongside its established operations.

For more information, visit www.bionexusgenelab.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about BGLC’s AI and healthcare strategy, including anticipated connections with its investments and VitaGuard work; plans to develop and commercialize its own AI applications; the expected contribution of CogniAI; GeneMatrix report-access and companion development; technology delivery, acceptance testing, licence activation and closing; plans to offer applications to government digitalization initiatives and the outcome of any public procurement; market size and growth projections; additional-industry opportunities; customer adoption; future royalties; and the benefits of the reciprocal share investment. Words such as “will,” “would,” “plan,” “intend,” “may,” “expect” and similar expressions identify forward-looking statements.

Actual results may differ materially because of technology delivery and acceptance; ownership and third-party rights; any required PRC technology-export approvals; performance on English- and Malay-language records and integration environments; data protection, cybersecurity and healthcare regulation; development readiness; implementation resources and funding; the parties’ financial condition, including going-concern uncertainties disclosed in their filings; customer demand, government budgets, priorities and procurement outcomes, and competition; the accuracy of third-party market estimates, which BGLC has not independently verified; share-price volatility, dilution and investment impairment; and accounting judgments. The agreement does not assure closing, customer contracts, revenue, profitability or clinical outcomes. Additional risks appear in BGLC’s latest Form 10-K, subsequent Forms 10-Q and other SEC filings. Forward-looking statements speak only as of the date made. BGLC undertakes no obligation to update them except as required by law.

Investor Relations and Corporate Communications

BioNexus Gene Lab Corp.
ir@bionexusgenelab.com

PLANTATION, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — Alliance Entertainment Holding Corporation (Nasdaq: AENT), a scaled entertainment commerce and collectibles platform serving content owners, brands, retailers and fans across music, movies, gaming, licensed merchandise and collectibles, with proprietary brands, authentication technology and reach across more than 35,000 retail and e-commerce storefronts, today announced its participation in two upcoming investor conferences in New York City during October 2026.

Maxim Growth Summit 2026 – October 13-14, 2026

Jeff Walker, Chief Executive Officer of Alliance Entertainment, will participate in the Maxim Growth Summit 2026 at the Hard Rock Hotel in New York City, delivering a company presentation on October 13.

Walker will also participate in the Consumer & Lifestyle panel from 9:00 a.m. to 10:00 a.m. ET on October 13, discussing the potential impact of agentic commerce on retail sales and how companies are responding to evolving consumer behaviors and preferences.

The ThinkEquity Conference – October 15, 2026

Walker will be joined by Bruce Ogilvie, Executive Chairman of Alliance Entertainment, for a company presentation at 10:30 a.m. ET in South Salon II at The ThinkEquity Conference, being held at the Mandarin Oriental Hotel in New York City.

Management will also be available for one-on-one investor meetings in connection with the conferences. Interested investors should contact their respective conference representatives to request meetings with Alliance Entertainment management.

About Alliance Entertainment

Alliance Entertainment (NASDAQ: AENT) is a scaled entertainment commerce and collectibles platform serving content owners, brands, retailers and fans across music, movies, gaming, licensed merchandise and collectibles. The Company also owns and develops proprietary brands and platforms, including Handmade by Robots™ and Alliance Authentic™, while Endstate Authentic adds NFC-enabled authentication and digital product identity capabilities supporting provenance, brand protection and authenticated resale. Leveraging decades of industry relationships and distribution, fulfillment and inventory-management expertise, Alliance reaches more than 35,000 retail and e-commerce storefronts, connecting entertainment franchises and collectible products with consumers across channels and generations. For more information, visit www.aent.com.

For investor inquiries, please contact:

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
AENT@redchip.com

Integrated Technology Supports Faster Transactions and Streamlined Operations Across Sports, Concerts and Global Events

MILWAUKEE, Oct. 07, 2026 (GLOBE NEWSWIRE) — Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology, today announced that Hard Rock Stadium has selected Clover Sport as its official point-of-sale technology partner, bringing Fiserv’s integrated venue technology to one of the world’s premier sports and entertainment destinations. This deployment establishes Clover Sport as the technology supporting commerce across Hard Rock Stadium’s full calendar of professional sports, international competitions, concerts and large-scale live events, with capabilities designed to support transaction speed, operational efficiency and fan experiences.

Clover Sport is now live at Hard Rock Stadium, supported by 1,020 Clover Station Duo terminals and integrated scanners, along with 50 Clover Flex handheld units deployed across the venue. By combining payment processing, hardware, and ticketing software integration into a unified system, Fiserv provides venue operators with centralized management, real-time reporting, and uninterrupted performance during peak event rushes.

“Modern venue operations require high-performance technology that performs flawlessly under the most demanding conditions,” said Robert Clarkson, Chief Revenue Officer, SMB and Clover, at Fiserv. “Working with Hard Rock Stadium will allow us to deliver a modernized, fast commerce experience for millions of fans. By bringing Clover Sport to the venue, we’re helping create faster, more seamless experiences for fans while delivering the operational intelligence and reliability venue operators need to perform at scale.”

The Hard Rock Stadium operations team will have access to centralized reporting and actionable business insights, enabling them to streamline back-of-house operations.

“Technology plays a critical role in how fans experience sports and entertainment events,” said Sameer Istafa, Vice President and Chief Technology Officer at the Miami Dolphins and Hard Rock Stadium. “Clover Sport provides a modern point-of-sale platform that helps our guests spend less time waiting in line and more time enjoying the action, while giving our concessions team the technology they need to operate at peak efficiency.”

Clover Sport powers commerce at more than 60 major entertainment venues across NCAA and professional sports, demonstrating the platform’s scale across the sports and entertainment market. The deployment of Clover Sport’s technology across this venue underscores Fiserv’s growing leadership in modernizing enterprise sports and entertainment destinations worldwide.

For more information about Clover, visit www.clover.com.

About Fiserv

Fiserv, Inc. (NASDAQ: FISV), a Fortune 500 company, is a global leader uniting commerce and finance. The company powers sustained growth and innovation at scale for financial institutions and businesses worldwide across payments, account processing, digital banking, merchant acquiring, network services, e-commerce, and Clover^®, the all-in-one business management platform. Fiserv is a member of the S&P 500^® Index and one of FORTUNE^® America’s Most Innovative Companies. Visit fiserv.com and follow on social media for more information and the latest company news.

Media Relations:

Fiserv, Inc.
Melissa Moritz
Vice President, External Communications
melissa.moritz@fiserv.com

New dedicated website will showcase the evolution of Fusemachines’ AI Twin technology while inviting discussion on the technical, legal, social, and human implications of AI that can represent people at work

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) — Fusemachines Inc. (NASDAQ: FUSE) (“Fusemachines” or the “Company”), a leading provider of enterprise AI products and services, today announced the launch of fuse.ai, a website dedicated to the Company’s emerging AI Twin technology and the broader questions surrounding a future in which AI systems may increasingly represent people in the workplace.

Fusemachines is introducing fuse.ai as a platform for its AI Twin research, technology demonstrations, and discussion of how AI could represent individuals in the workplace.

The initiative explores a fundamental idea: Can AI extend an individual’s presence, knowledge, perspective, and participation at work? The Company envisions AI Twins that could eventually attend meetings, contribute to discussions, share context, and support decisions within clearly defined boundaries.

The site features an illustrative demonstration of AI Twin technology participating in a workplace meeting, offering an early look at the technology under development.

“We have talked for years about our north star of fusing machines with humans,” said Sameer Maskey, Founder and CEO of Fusemachines. “AI Twins is our effort to bring that vision closer to reality and expand what people can do and where they can be present.”

The initiative reflects Fusemachines’ #OnHumanTerms philosophy: the belief that AI should be developed around human values, agency, transparency, and accountability. When a Twin speaks, does it convey the individual’s opinion, an inference, or an authorized decision? What authority should it have? Who is accountable, and how should consent, privacy, and confidential information be protected?

“How do we preserve trust, consent, and human agency when AI represents a person?” said Taylor Allen, Senior Director of People at Fusemachines. “These questions need to be considered while the technology is being built, not after it is deployed.”

Reliably representing an individual presents substantial technical challenges, including understanding context, maintaining memory, distinguishing knowledge from opinion, respecting permissions, and recognizing changing viewpoints.

“Building AI that answers questions is different from building AI that reliably represents a person,” said Anish Joshi, Head of Technology at Fusemachines. “The system must recognize uncertainty, understand its boundaries, and know when to bring the human back into the loop.”

Fusemachines plans to share updated demonstrations, experiments, and perspectives on AI Twins’ technical, legal, organizational, social, and ethical implications, and intends to invite employees, business leaders, technologists, policymakers, researchers, and the public to help shape the conversation.

Visit fuse.ai to view the demonstration, follow the research, and explore the questions guiding #OnHumanTerms.

About Fusemachines
Founded in 2013, Fusemachines is a global provider of enterprise AI products and services, on a mission to democratize AI. Leveraging proprietary AI Studio, AI Engines and AI Agents, the Company helps drive clients’ AI Enterprise Transformation, regardless of where they are in their Digital AI journeys. With offices in North America, Asia and Latin America, Fusemachines provides a suite of enterprise AI offerings and specialty services that allow organizations of any size to implement and scale AI.

Fusemachines continues to actively pursue the mission of democratizing AI by providing high-quality AI education in underserved communities and helping organizations achieve their full potential with AI.

To learn about Fusemachines, visit www.fusemachines.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the development, anticipated capabilities, potential uses, and timing of the Company’s AI Twin technology; the planned content and evolution of the fuse.ai website, including future demonstrations and experiments; the Company’s agentic AI programs, product development initiatives, commercialization strategy, enterprise AI offerings, and expected market opportunities. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “envision,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” “would,” and similar expressions.

These forward-looking statements are based on current expectations, estimates, assumptions, and projections and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk that the Company’s AI Twin technology may not be successfully developed, may not achieve the capabilities described, or may never be commercialized; technical challenges in building AI systems that can reliably represent individuals, including risks of inaccurate, unauthorized, or unintended actions or communications; uncertain and evolving laws, regulations, and standards governing artificial intelligence, privacy, consent, identity, likeness, and the use of AI on behalf of individuals; potential reputational harm or liability associated with AI Twin technology; risks related to customer adoption and retention; the Company’s ability to develop, maintain, and enhance its products and platform; the ability of the Company’s AI solutions to deliver expected operational and business benefits; reliance on third-party platforms, partners, data, and infrastructure; competition in the markets in which the Company operates; cybersecurity, data privacy, regulatory, and intellectual property risks; and changing macroeconomic, industry, and market conditions.

Additional information regarding these and other risks and uncertainties is included in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K filed with the SEC on March 27, 2026, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Forward-looking statements speak only as of the date they are made, and Fusemachines undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Media Contact:

pr@fusemachines.com

Investor Contact:

ir@fusemachines.com

+1 347 212-5075

 

Hong Kong, Oct. 07, 2026 (GLOBE NEWSWIRE) — Mint Incorporation Limited (“Mint” or the “Company”, together with its subsidiaries, the “Group”, NASDAQ: MIMI), a Hong Kong-based company strategically focused on artificial intelligence (AI) and robotics as its primary growth engine, today announced that Axonex Robotics Limited (“Axonex”), its majority-owned subsidiary, has entered into an OEM Supply and License Agreement (the “Agreement”) with Centridex Limited (“Centridex”), a company incorporated in Ireland. Under the two-year Original Equipment Manufacturer (“OEM”) programme, which has a total potential value of approximately €3 million over the programme period, the parties have agreed an initial order package worth approximately €450,000, covering robot kits and platform licensing arrangements. Axonex will supply robot kits, platform licenses, standard, software and platform technology to Centridex, which would assemble, test and distribute the finished robots in Ireland and other selected markets.

The Agreement reflects the Group’s strategy of expanding its international footprint by supplying its robot kits and platform to overseas markets. Under the programme, from October 1, 2026 to September 30, 2028, the Group will design, manufacture and ship kits of parts, sub-assemblies, firmware and documentation for four product categories: the M3 robot kit, the Sumo cleaning robot kit, the Nex-class half-humanoid robot kit and the R-300 educational robot kit. Centridex will receive the kits in Ireland, assemble, test and resell the finished robots to its customers. The Group will also license its software and platform to Centridex and develop a Centridex-branded platform derived from the Group’s current robot model. The collaboration is intended to serve as a gateway for Axonex’s robotics solutions into Europe, leveraging local assembly and distribution capabilities to support future market expansion across the region.

As part of the Agreement, the parties have agreed an initial order for package valued at approximately €450,000, covering robot kits, platform licensing and related services under the programme. Future purchase orders and commercial schedules will be implemented under the framework of the Agreement.

Mr. Damian Chan, Chairman of the Board and Chief Executive Officer of Mint, stated: “This Agreement marks an important milestone in our international growth strategy and reflects the increasing demand for scalable robotics solutions beyond Asia. Through local assembly and distribution in Ireland, we believe the programme could establish a foundation for broader access to European customers. Working with Centridex as our local assembler and reseller, we aim for it to become a sales channel for Axonex technology in Europe, bringing a broader range of robotics solutions, including educational robots, cleaning robots and  our flagship Nex-class semi-humanoid robot, to customers across Europe. We look forward to working closely with Centridex to commence implementation of the programme and deliver the first shipment of kits, laying the groundwork for the next stage of Axonex’s international growth.”

Mr. Milan Urbanczyk, Managing Director of Centridex, added: “We are pleased to sign this Agreement with Axonex. The programme will allow us to broaden our product portfolio with robots assembled in Ireland from Axonex kits, and we are confident these robots will appeal to our customers. We look forward to implementing the programme and building a lasting relationship with Axonex.”

The Agreement is non-exclusive and establishes the framework governing the OEM supply, platform licensing and Ireland-based assembly arrangement. Future purchase orders, product specifications and commercial schedules will be implemented in accordance with the Agreement.

– End-

About Mint Incorporation Limited  

Mint Incorporation Limited (NASDAQ: MIMI) is a Hong Kong-based company listed on NASDAQ, strategically focused on artificial intelligence (AI), robotics, and interior design. Through its wholly-owned subsidiary Axonex AI Limited (Axonex AI), and through its majority-owned subsidiary Axonex Robotics Limited (Axonex Robotics), Mint delivers comprehensive intelligent automation solutions. Axonex AI specializes in smart facility management, integrating robotics, IoT, physical AI solutions such as humanoid robots and AI-powered analytics to provide real-time monitoring and predictive insights. In addition, through Matter International Limited, the Group provides professional interior design and fit-out services. Anchored by innovation and practical application, Mint is committed to enhancing efficiency, safety, and quality of life across industries.

About Centridex Limited  

Centridex Limited is a technology trading company incorporated in Ireland and headquartered in Dublin. The company sources technology products from suppliers worldwide, including robotics and smart platforms, and supplies them to customers internationally.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results, and encourages investors to review other factors that may affect its future results disclosed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”).

Media Enquiries
Strategic Financial Relations Limited
Vicky Lee	Tel: (852) 2864 4834	E-mail: vicky.lee@sprg.com.hk
Rachel Ko	Tel: (852) 2114 2370	E-mail: rachel.ko@sprg.com.hk
Cherrie Man	Tel: (852) 2864 4846	E-mail: cherrie.man@sprg.com.hk
Mint Incorporation Limited
Investor and Media Relations	[info@mimintinc.com]	[http://www.mimintinc.com/ ]

Board Maintains Quarterly Cash Dividend at $0.22 Per Share; Payable November 24, 2026

BOCA RATON, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — Q.E.P. CO., INC. (OTCQX: QEPC) (“QEP” or the “Company”) today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.22 per share on the Company’s common stock.

The dividend will be payable on November 24, 2026, to stockholders of record as of the close of business on November 6, 2026.

The dividend reflects QEP’s ongoing commitment to disciplined capital allocation and its focus on generating long-term value for stockholders.

About QEP

Founded in 1979, Q.E.P. Co., Inc. is a leading designer, manufacturer and distributor of a broad range of best-in-class flooring installation solutions for commercial and home improvement projects. QEP offers a comprehensive line of specialty installation tools, adhesives, and underlayment products. QEP sells its products worldwide through home improvement retail centers and professional specialty distribution outlets under brand names including QEP®, LASH®, ROBERTS®, Capitol®, Spray-Lock®, Premix-Marbletite® (PMM), Brutus®, and Homelux®.

QEP is headquartered in Boca Raton, Florida and operates additional facilities in the United States, Canada and Asia.

For more information, please visit our website at www.qep.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include statements regarding the Company’s capital allocation strategy, commitment to shareholder returns, generation of long-term stockholder value, financial flexibility, growth initiatives, and other statements that are not historical facts. These statements are based on current expectations and assumptions and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

Such risks and uncertainties include, among others, changes in general economic and business conditions; inflationary pressures; tariffs, trade policies, and geopolitical developments; fluctuations in raw material, labor, freight, and energy costs; supply chain disruptions; competitive market conditions; customer demand; and the other risks and uncertainties described in the Company’s public disclosures. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

CONTACT:
Q.E.P. Co., Inc.
Enos Brown
Executive Vice President and
Chief Financial Officer
561-994-5550

Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions 

Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Delivering Savings, Total Cost Management and ROI

Progyny’s Solutions Creating Compelling Opportunities for Employers to Stem Impacts from Broader Medical Cost Inflation Trend While Maintaining or Expanding Coverage of Services Impactful to their Workforce

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women’s health and family building solutions, today revealed key insights from the Company’s current annual selling season, based on both commitments received to date and anticipated remaining decisions which are expected to contribute 1.2 million new covered lives from launches throughout the first half of 2027.

Employers are now weighing how to best meet the complex needs of their workforce while simultaneously wrestling with the broader escalation in the overall medical cost trend. Progyny’s solutions are addressing very real and highly prevalent medical needs for women and families, making these categories particularly relevant to today’s workforce.

This season, Progyny is seeing the savviest and most data-intensive employers meet this challenge — whether or not they currently provide coverage for infertility — by leaning into those benefit managers, like Progyny, who have a proven history of mitigating that broader cost trend through programs that drive savings through a combination of superior clinical outcomes and effective total cost management.

“With the commitments we have received to date and anticipated remaining decisions, our selling season is pacing to a potential record level for new lives added for our managed fertility solution,” said Pete Anevski, Chief Executive Officer, Progyny. “We believe it isn’t coincidental that we’re seeing these strong results given the expected record increases in the overall medical plan cost in 2027.”

While buyers continue to be focused on cost, quality, and member experience, there is also a heightened focus on accountability and a proven track record of success. Progyny’s innovative program has demonstrated a consistent ability to increase the effectiveness of fertility treatment while lowering the risk of costly complications, including high-risk pregnancies, miscarriages, and multiple births.

“For those employers actively looking for ways to maintain or expand the family building services they are providing to their workforce in 2027, and who recognize the importance of doing so in a fiscally responsible way, Progyny’s standard practice includes an accelerated contracting path when working through one of our many channel partners and our best-in-class implementation timetable,” concluded Anevski.

For Further Information, Please Contact:

Investors:
James Hart
investors@progyny.com

Media:
Alexis Ford
media@progyny.com

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.

Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women’s health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes’ Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2026; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2027 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words “anticipates,” “assumes,” “believe,” “contemplate,” “continues,” “could,” “estimates,” “expects,” “future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,” “should,” “target,” “will,” and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.

Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the “SEC”), including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent reports that we file with the SEC, which are available at http://investors.progyny.com and on the SEC’s website at https://www.sec.gov.

Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons.